Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were down 6.9% during mid-day trading on Friday . The company traded as low as $84.29 and last traded at $84.52. Approximately 734,055 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 822,006 shares. The stock had previously closed at $90.74.
A number of analysts have issued reports on ALNY shares. Morgan Stanley raised Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price target on the stock in a research note on Tuesday, March 5th. ValuEngine downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. Piper Jaffray Companies lowered their price target on Alnylam Pharmaceuticals to $152.00 and set an “overweight” rating for the company in a report on Tuesday, January 15th. UBS Group started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 23rd. They issued a “neutral” rating and a $87.00 price target for the company. Finally, Guggenheim started coverage on Alnylam Pharmaceuticals in a research report on Monday, December 17th. They set a “buy” rating and a $105.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $132.06.
The company has a debt-to-equity ratio of 0.02, a current ratio of 6.69 and a quick ratio of 6.56. The firm has a market capitalization of $8.98 billion, a price-to-earnings ratio of -11.17 and a beta of 2.61.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 7th. The biopharmaceutical company reported ($2.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.27) by $0.18. Alnylam Pharmaceuticals had a negative return on equity of 50.82% and a negative net margin of 1,016.58%. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $18.03 million. During the same quarter last year, the business posted ($1.20) EPS. The company’s revenue for the quarter was down 44.6% on a year-over-year basis. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -9.02 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Comerica Bank boosted its stake in Alnylam Pharmaceuticals by 36.9% during the 3rd quarter. Comerica Bank now owns 22,088 shares of the biopharmaceutical company’s stock valued at $1,692,000 after purchasing an additional 5,956 shares during the period. Wells Fargo & Company MN boosted its holdings in Alnylam Pharmaceuticals by 1.6% in the 3rd quarter. Wells Fargo & Company MN now owns 199,949 shares of the biopharmaceutical company’s stock valued at $17,499,000 after purchasing an additional 3,146 shares during the period. SG Americas Securities LLC boosted its holdings in Alnylam Pharmaceuticals by 97.4% in the 3rd quarter. SG Americas Securities LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $825,000 after purchasing an additional 4,652 shares during the period. Toronto Dominion Bank boosted its holdings in Alnylam Pharmaceuticals by 9.7% in the 3rd quarter. Toronto Dominion Bank now owns 9,827 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 869 shares during the period. Finally, Prudential Financial Inc. boosted its holdings in Alnylam Pharmaceuticals by 110.2% in the 3rd quarter. Prudential Financial Inc. now owns 73,444 shares of the biopharmaceutical company’s stock valued at $6,427,000 after purchasing an additional 38,500 shares during the period. Institutional investors own 85.69% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals (ALNY) Trading Down 6.9%” was originally published by Highlight Press and is the sole property of of Highlight Press. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://highlightpress.com/2019/03/24/alnylam-pharmaceuticals-alny-trading-down-6-9.html.
Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Further Reading: Growth Stocks
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.